Mavenclad (Cladribine Tablets) Receives First Approval in the Middle East & Africa Region

DARMSTADT, Germany, April 9, 2018/PRNewswire/ —

  • First oral short-course treatment for highly active relapsing multiple sclerosis (RMS) now approved in United Arab Emirates
  • Mavencladhas shown sustained clinical efficacy for up to 4 years with a maximum of